Health care stocks were mixed premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was up 0.1% and the iShares Biotechnology ETF (IBB) was down 0.4%.

Edgewise Therapeutics (EWTX) shares soared 14% after it said a phase 2 trial of sevasemten to treat patients with Becker muscular dystrophy met its primary endpoint of change from baseline in creatine kinase.

PureTech Health (PRTC) shares jumped 13% after it said that a phase 2 clinical trial of its drug deupirfenidone as a treatment of patients with idiopathic pulmonary fibrosis reached its primary endpoint.

Foghorn Therapeutics (FHTX) shares fell 17% after it said it has decided to discontinue the independent development of FHD-286 in combination with decitabine to treat patients with relapsed and/or refractory acute myeloid leukemia.